Captor Therapeutics SA () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BIOTON SA

Biogened SA

Celon Pharma SA

Ryvu Therapeutics SA

Captor Therapeutics SA

Synthaverse SA

Bioceltix SA

Molecure SA

E-shopping Group SA

Why is Captor Therapeutics SA ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate -5.88% of over the last 5 years

The company has declared negative results in Dec'2024 after 3 consecutive positive quarters

INTEREST(9M) At PLN 0.35 MM has Grown at 54.87%
RAW MATERIAL COST(Y) Grown by 57.42% (YoY)
DEBT-EQUITY RATIO (HY) Highest at -22.04 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 36.42%, its profits have risen by 15.4%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Captor Therapeutics SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Captor Therapeutics SA

36.42%

-0.19

49.80%

Poland WIG

39.24%

1.93

20.32%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

29.28%

EBIT Growth (5y)

-5.88%

EBIT to Interest (avg)

-57.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.57

Sales to Capital Employed (avg)

0.26

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.10

EV to EBIT

-3.63

EV to EBITDA

-4.05

EV to Capital Employed

-58.22

EV to Sales

16.26

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-88.12%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

OPERATING CASH FLOW(Y)

Highest at PLN 1.44 MM

NET PROFIT(HY)

Higher at PLN -19.48 MM

-20What is not working for the Company

INTEREST(9M)

At PLN 0.35 MM has Grown at 54.87%

RAW MATERIAL COST(Y)

Grown by 57.42% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -22.04 %

NET SALES(Q)

Lowest at PLN 2.61 MM

OPERATING PROFIT(Q)

Lowest at PLN -10.47 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -401.61 %

PRE-TAX PROFIT(Q)

Lowest at PLN -10.72 MM

NET PROFIT(Q)

Lowest at PLN -10.72 MM

Here's what is working for Captor Therapeutics SA

Operating Cash Flow

Highest at PLN 1.44 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (PLN MM)

Here's what is not working for Captor Therapeutics SA

Net Sales

At PLN 2.61 MM has Fallen at -42.15%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (PLN MM)

Interest

At PLN 0.35 MM has Grown at 54.87%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (PLN MM)

Net Sales

Lowest at PLN 2.61 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (PLN MM)

Operating Profit

Lowest at PLN -10.47 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (PLN MM)

Operating Profit Margin

Lowest at -401.61 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at PLN -10.72 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (PLN MM)

Net Profit

Lowest at PLN -10.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (PLN MM)

Debt-Equity Ratio

Highest at -22.04 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 57.42% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales